Voyager Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $5,200 | $6,473 | $6,278 | $24,629 |
Gross Profit | 5,200 | 6,473 | 6,278 | 24,629 |
EBITDA | -35,560 | -33,679 | -37,288 | -12,648 |
EBIT | -36,625 | -34,693 | -38,299 | -13,780 |
Net Income | -33,382 | -31,021 | -34,487 | -9,044 |
Net Change In Cash | 5,200 | 6,473 | 6,278 | 24,629 |
Free Cash Flow | -34,366 | -38,553 | -14,684 | -28,226 |
Cash | 43,940 | 74,755 | 71,367 | 112,525 |
Basic Shares | 58,666 | 58,349 | 57,974 | 57,851 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $80,001 | $250,008 | $40,907 | $37,415 |
Gross Profit | 80,001 | 245,567 | 40,907 | 37,415 |
EBITDA | -78,556 | 126,455 | -44,646 | -68,453 |
EBIT | -83,287 | 122,014 | -50,837 | -73,618 |
Net Income | -65,002 | 132,330 | -46,408 | -66,032 |
Net Change In Cash | 80,001 | 250,008 | 40,907 | 37,415 |
Cost of Revenue | -18,738 | 12,993 | ||
Free Cash Flow | -18,831 | 74,663 | -15,000 | -55,134 |
Cash | 71,367 | 68,802 | 98,959 | 117,433 |
Basic Shares | 57,667 | 44,569 | 38,356 | 37,668 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.57 |
2025-03-31 | -$0.53 |
2024-12-31 | -$0.59 |
